Audited Supplier
Retatrutide
2381089-83-2
N/a
200-001-8
Synthesis Material Intermediates
Powder
Refined
White
Standard
Laboratory Reagents
Dry Powder
Fine Chemicals
Scientific Research
Protein and Peptide
Research Use Only
Research Use
Retatrutide
2381089-83-2
No Tfa Salt
Authoried Regluar Workshop
1g/Bottle
2mg 5mg 10mg 15mg
Research Use Only
Hoconbio
Customized
1G/Bottle 2mg/5mg/10mg per vial
China
Product Description
Retatrutide is a triple hormone (GIP, GLP-1 and glucagon) receptor agonist in development for the treatment of obesity.
| Product Name | Retatrutide |
| CAS NO. | 2381089-83-2 |
| Other name | LY3437943 GIPR/GLP-1R |
| Appearance | White freeze-dried powder |
| Purity | 98% HPLC |
| Application | Research peptides |
| Shelf Life | 24 Months |
| Storage | Store at a temperature of 2-8 degrees, protected from light. |
- Treatment of depression and anxiety disorders: Retatrutide has been shown to have antidepressant and anxiolytic effects in preclinical studies, suggesting that it could be a promising treatment option for individuals with these conditions.
- Prevention of neurodegenerative diseases: Retatrutide has neuroprotective properties that may be useful in preventing or slowing the progression of neurodegenerative diseases such as Alzheimer's and Parkinson's.
- Enhancement of cognitive function: Retatrutide has been shown to improve learning and memory in animal studies, suggesting that it could have potential as a cognitive enhancer in humans.
- Treatment of chronic pain: Retatrutide has been shown to have analgesic effects in preclinical studies, suggesting that it could be a useful treatment option for individuals with chronic pain conditions.
- Promotion of wound healing: Retatrutide has been shown to accelerate wound healing in animal studies, suggesting that it could have potential as a therapeutic agent for promoting wound healing in humans.
